Glucagon Market Report
The Global Glucagon Market report is segmented By Product Type (Inject Glucagon, Nasal Glucagon), Application (Emergency Use, General Use, Diagnostics & Motility, Others), and Region. It also covers the COVID-19 Impact Analysis and Forecast to 2026. This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global Glucagon market. The historic years considered for the study are 2016-2019, base year is 2020, the estimated year is 2021, and the forecast period is 2022-2026.
The Global Glucagon Market report is segmented By Product Type (Inject Glucagon, Nasal Glucagon), Application (Emergency Use, General Use, Diagnostics & Motility, Others), and Region. It also covers the COVID-19 Impact Analys...
Impact of COVID-19 on Glucagon Market
Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.
Note: The summary below might not have included insights on covid impact since we have large number of reports.
The Global Glucagon Market is expected to grow from USD 486.6 million in 2020 to USD 689.2 million by 2026 at a CAGR of over 6.1% during the forecast period.
Figure: Global Glucagon Market Size, 2020-2026 (USD Million)
Wish to get a sample report? Click here.
Glucagon is defined as a hormone that is produced by the alpha cells in the pancreas and then is released into the bloodstream. It is used to control the blood sugar levels in the human body. It promotes the production of glucose from amino acid molecules. It works along with insulin to control the blood sugar levels and keep them within set levels.
Key players operating in the global Glucagon Market are-
An increasing number of people suffering from heart problems due to changing lifestyles and unhealthy eating habits is likely to drive the market growth significantly.
The growth of the global glucagon market is primarily driven by the increasing prevalence of hypoglycaemia among people suffering from diabetes. Growing emphasis on the development of innovative products such as non-injectable emergency glucagon by the market players is the prominent trend noticed in the global glucagon market. Furthermore, the development of advanced drugs and therapies to treat hypoglycaemia is likely to create lucrative growth opportunities in the global glucagon market.
Based on product type, the market has been segmented into injecting glucagon and nasal glucagon. The inject glucagon segment accounted for the largest market share in 2020 owing to widespread usage in the end-use applications.
Geographically, the market in North America accounted for the largest market share in 2020 and is projected to continue its dominance during the review period.
The covid-19 outbreak impacted the growth of the Glucagon market positively. People having diabetes were likely to face severe effects of the virus as compared to non-diabetic people. Thus, the demand for glucagon increased to maintain blood sugar levels. However, the supply of the product was affected for a short period amid lockdown as it resulted in restricted travel and supply chain disruptions.
To get a full scope of the report, click here…
Here is the list of the group of customers that the Global Glucagon market hopes to have the greatest opportunity to convert-
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at email@example.com.
The glucagon market is expected to witness an impressive growth of 6.1% CAGR in the coming years.
Fresenius SE & Co. KGaA (Germany), Eli Lilly & Co. (The U.S), Novo Nordisk A/S (Denmark), Xeris Pharmaceuticals, Inc. (The U.S), Svar Life Science AB (Sweden), Taj Pharmaceuticals Ltd. (India), Pfizer Inc (The U.S), Amgen Inc. (The U.S), Avalon Pharma Private Limited (India), Bachem Holding AG (Switzerland) and Fujifilm Holdings Corporation (Japan) are among the key players in the glucagon market.
The glucagon market is expected to reach USD 689.2 million in the foreseeable future.
North America is expected to remain dominant in the glucagon market in the coming years.
The inject glucagon segment accounted for the largest share of the glucagon market in 2020.
Increasing prevalence of hypoglycaemia among people suffering from diabetes, growing emphasis on the development of innovative products such as non-injectable emergency glucagon, development of advanced drugs and therapies to treat hypoglycaemia are the factors driving the growth of glucagon market.
Glucagon manufacturers, Glucagon suppliers, Glucagon distributors, Organizations, Government bodies are the target audience in the glucagon market.